The a2 Milk Co Ltd (ASX: A2M) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
The a2 Milk Co Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
The a2 Milk Co Ltd (ASX: A2M)
Latest News
⏸️ Investing
Here are 10 market-beating growth shares to buy in 2017
⏸️ Investing
3 growth shares I would buy this Easter
⏸️ Investing
3 companies I wouldn't buy for their global diversification
⏸️ Investing
ASX heads NOWHERE as banks slide lower
⏸️ Investing
3 reasons why I own shares in A2 Milk Company Ltd (Australia)
⏸️ Investing
In your 20's? Try these 3 ASX shares
⏸️ Investing
Reinvest your Commonwealth Bank of Australia dividends in these 3 ASX stars
⏸️ Investing
Why these 4 ASX shares went gangbusters in March
⏸️ Investing
The Yowie Group Ltd share price rockets 18%: Time to buy?
⏸️ Investing
Here's why these 6 explosive ASX shares have smashed the market in March
⏸️ Investing
Why these 3 ASX shares have stormed to 52-week highs
⏸️ Investing
Why these 4 ASX shares have started the week with a BANG
Frequently Asked Questions
-
The a2 Milk Company Ltd does not currently pay a dividend.
-
The a2 Milk Company Ltd does not currently have a dividend reinvestment program.
-
The company was founded in 2000 in New Zealand and listed on the ASX in March 2015.
A2M ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About The a2 Milk Co Ltd
A2 Milk Company Ltd (ASX: A2M) is a fresh milk and infant formula company that sources, produces and supplies a2 brand milk and milk-related products in Australia and globally.
The Company was founded in 2000 in New Zealand by scientist Dr Corran McLachlan and Howard Paterson.
The company produces fresh cows' milk that naturally contains the A2 protein type and no A1 protein. Some research suggests the A1 protein can cause digestion issues.
A2M Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
29 Nov 2024 | $5.75 | $0.02 | 0.35% | 1,911,944 | $5.73 | $5.80 | $5.68 |
28 Nov 2024 | $5.73 | $0.02 | 0.35% | 1,361,379 | $5.75 | $5.82 | $5.72 |
27 Nov 2024 | $5.71 | $0.18 | 3.25% | 2,332,295 | $5.54 | $5.77 | $5.52 |
26 Nov 2024 | $5.53 | $0.02 | 0.36% | 2,238,151 | $5.65 | $5.67 | $5.50 |
25 Nov 2024 | $5.51 | $0.06 | 1.10% | 3,677,782 | $5.50 | $5.68 | $5.45 |
22 Nov 2024 | $5.45 | $0.64 | 13.31% | 10,716,572 | $5.59 | $5.72 | $5.38 |
21 Nov 2024 | $4.81 | $-0.05 | -1.03% | 1,965,985 | $4.88 | $4.88 | $4.81 |
20 Nov 2024 | $4.86 | $-0.05 | -1.02% | 1,458,109 | $4.92 | $4.93 | $4.82 |
19 Nov 2024 | $4.91 | $-0.01 | -0.20% | 1,127,277 | $4.93 | $4.96 | $4.89 |
18 Nov 2024 | $4.92 | $0.11 | 2.29% | 2,061,480 | $4.82 | $4.94 | $4.79 |
15 Nov 2024 | $4.81 | $-0.09 | -1.84% | 1,855,320 | $4.92 | $4.95 | $4.80 |
14 Nov 2024 | $4.90 | $0.12 | 2.51% | 2,529,308 | $4.78 | $4.90 | $4.76 |
13 Nov 2024 | $4.78 | $-0.04 | -0.83% | 3,425,795 | $4.80 | $4.87 | $4.73 |
12 Nov 2024 | $4.82 | $-0.10 | -2.03% | 6,595,003 | $4.95 | $4.95 | $4.77 |
11 Nov 2024 | $4.92 | $-0.36 | -6.82% | 5,608,810 | $5.30 | $5.30 | $4.89 |
08 Nov 2024 | $5.28 | $0.09 | 1.73% | 3,614,439 | $5.23 | $5.29 | $5.14 |
07 Nov 2024 | $5.19 | $-0.13 | -2.44% | 4,171,502 | $5.26 | $5.29 | $5.19 |
06 Nov 2024 | $5.32 | $-0.16 | -2.92% | 2,402,885 | $5.46 | $5.50 | $5.32 |
05 Nov 2024 | $5.48 | $-0.11 | -1.97% | 2,911,127 | $5.56 | $5.57 | $5.39 |
04 Nov 2024 | $5.59 | $-0.12 | -2.10% | 2,148,664 | $5.70 | $5.71 | $5.56 |
01 Nov 2024 | $5.71 | $-0.06 | -1.04% | 1,122,735 | $5.70 | $5.78 | $5.69 |
31 Oct 2024 | $5.77 | $0.02 | 0.35% | 1,983,122 | $5.73 | $5.84 | $5.68 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
30 Aug 2024 | David Bortolussi | Buy | 490,906 | $2,744,164 |
Conversion of securities.
|
30 Aug 2024 | David Bortolussi | Exercise | 490,906 | $2,744,164 |
Conversion of securities. 1,191,246 performance rights
|
15 Dec 2023 | David Bortolussi | Issued | 690,066 | $2,794,767 |
Issue of securities. 1,682,152 performance rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David Landt Bortolussi | Chief Executive OfficerManaging Director | Feb 2021 |
Mr Bortolussi career has been focused on the consumer and retail sector in Australia and New Zealand complemented by international experience in various markets and categories in China, SE Asia, the EU and the USA. David also has an interest in private equity and growth-phase businesses. He is a member of the advisory board of Whiteoak and supports the development of investee companies.
|
Ms Philippa (Pip) Mary Greenwood | Non-Executive Director | Jul 2019 |
Ms Greenwood is also the Chair of Westpac New Zealand and a director of Fisher & Paykel Healthcare. She was previously a director of Spark New Zealand and Vulcan Steel. Prior to becoming a full-time director, Pip was a senior partner at law firm Russell McVeagh, where she spent over 10 years on the firm's Board including acting as the firm's Board Chair and interim CEO.
|
Ms Kathryn(Kate) Mitchell | Non-Executive Director | Jun 2023 |
Ms Mitchell has governance experience as a director of both private and public companies. Prior to moving to New Zealand in 2014, Kate's executive career spanned over 20 years in investment banking in London, which included senior leadership roles in the Global Markets division within investment banks including Deutsche Bank, Goldman Sachs and Merrill Lynch. She also has experience in developing solutions for clients, particularly in the areas of financial risk management, structured financing and investments. She is also Chair of the Risk Management Committee.
|
Ms Sandra Yu | Non-Executive Director | Mar 2022 |
Ms Yu is a company director and a global executive in consumer goods industries, and importantly in the infant milk formula (IMF) market in China, with a proven track record of driving business and brand transformation, leveraging opportunities for growth, and building organizational capabilities across China as well as the USA and other parts of Asia. Prior to that, Sandra held various other senior executive roles at Mead Johnson Nutrition, including as the Global Marketing Vice President, responsible for transition to new digital media and e-commerce channels globally.
|
Mr David Wang | Non-Executive Director | Sep 2022 |
Mr Wang brings expertise across the Asia-Pacific region in manufacturing and supply chain with over 30 years of experience in industrial and consumer goods businesses including 15 years in senior executive leadership roles in China and international. In his career, David has held various senior executive roles including at Blackstone AVINTIV Inc and Dover Corporation where his responsibilities covered manufacturing, research and development, technology, sales and marketing throughout Asia. David sits on both the Risk Management and the People and Remuneration Committees.
|
Mr Antonio (Tonet) Rivera | Non-Executive Director | Nov 2024 |
Mr Rivera has over 35 years of supply chain experience, including 17 years of international leadership experience. Mr Rivera worked for Mead Johnson Nutrition from 2002 to 2017, in four years leading the global supply chain of the multinational nutrition company in the role of Senior Vice President, Global Supply Chain. Prior to that, he served as Vice President, Supply Chain - Asia and Europe for more than a decade, with responsibility for Supply Chain operations in Europe and Asia, including owned manufacturing locations and third-party manufacturers. Since retiring from executive roles in 2017, when Mead Johnson Nutrition was acquired by Reckitt Benckiser Group plc, Mr Rivera has worked as a supply chain consultant.
|
Mr Jaron McVicar | Company SecretaryGeneral Counsel | Nov 2016 |
-
|
Jaron McVicar | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 113,290,528 | 15.67% |
Citicorp Nominees Pty Limited | 96,163,814 | 13.30% |
BNP Paribas Nominees NZ Limited Bpss40* | 42,529,528 | 5.88% |
J P Morgan Nominees Australia Pty Limited | 34,661,044 | 4.79% |
HSBC Nominees (New Zealand) Limited* | 26,156,306 | 3.62% |
Tea Custodians Limited* | 21,013,734 | 2.91% |
HSBC Custody Nominees (Australia) Limited Gsco Eca | 20,980,543 | 2.90% |
Accident Compensation Corporation* | 20,509,205 | 2.84% |
JPMORGAN Chase Bank* | 18,595,095 | 2.57% |
New Zealand Superannuation Fund Nominees Limited* | 17,659,815 | 2.44% |
Citibank Nominees (NZ) Ltd* | 15,787,511 | 2.18% |
New Zealand Depository Nominee | 14,021,429 | 1.94% |
National Nominees Limited | 13,425,469 | 1.86% |
HSBC Nominees (New Zealand) Limited* i | 9,463,432 | 1.31% |
Premier Nominees Limited* | 8,473,699 | 1.17% |
Public Trust* | 7,323,398 | 1.01% |
UBS Nominees Pty Ltd | 6,938,917 | 0.96% |
New Zealand Permanent Trustees Limited* | 6,325,699 | 0.88% |
BNP Paribas Noms Pty Ltd | 6,123,304 | 0.85% |
JBWere (NZ) Nominees Limited | 5,945,531 | 0.82% |